USPTO Art Unit 1682 Prosecution Statistics

Art Unit Information

Art Unit: 1682
Group: 1680
Tech Center: 1600
Total Cases: 1,285
Last Active: June 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19252300ALLELE, MOLECULAR MARKER, AND PRIMER PAIR OF RICE HPS1 GENE, AND APPLICATIONS THEREOFJune 2025December 2025Allow620YesNo
19181901METHODS AND SYSTEMS FOR DETECTING A PRIMARY DISEASEApril 2025September 2025Allow510YesNo
19035409MYC AMPLIFICATION DRIVES RESISTANCE TO PAN-RAS INHIBITORS IN PANCREATIC CANCERJanuary 2025February 2026Allow1311NoNo
18999227METHODS FOR TREATING NEUROBLASTOMADecember 2024January 2026Allow1330YesNo
18989169Compositions and Methods for Analyte DetectionDecember 2024November 2025Abandon1111YesNo
18953769BIOMARKERS AND USES THEREFORNovember 2024January 2026Allow1421NoNo
18941352MULTI-DIAGNOSTIC KIT FOR MOSQUITO-BORNE DISEASES AND METHOD FOR THE DIAGNOSIS OF THE DISEASESNovember 2024August 2025Allow1020NoNo
18919170FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOODOctober 2024August 2025Abandon1001NoNo
18889250METHOD TO CHARACTERIZE NUCLEIC ACIDSeptember 2024January 2026Abandon1620YesNo
18829672Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGFSeptember 2024October 2025Allow1431YesYes
18821044METHODS FOR ENRICHING A TARGET POLYNUCLEOTIDE IN A SAMPLEAugust 2024March 2025Allow610YesNo
18812678METHODS OF TREATING PSORIASISAugust 2024January 2026Allow1721NoNo
18803351IDENTIFICATION AND USE OF CIRCULATING NUCLEIC ACID TUMOR MARKERSAugust 2024April 2025Allow811YesNo
18802544MOLECULAR MARKER SIGNIFICANTLY ASSOCIATED WITH VITAMIN E CONTENT IN SOYBEANS, KOMPETITIVE ALLELE SPECIFIC POLYMERASE CHAIN REACTION PRIMERS COMBINATION AND APPLICATION THEREOFAugust 2024December 2024Allow500YesNo
18763579METHODS OF CAPTURING TARGET ANALYTESJuly 2024July 2025Abandon1320NoNo
18752771GENE SIGNATURES FOR CANCER CHARACTERIZATION AND TREATMENTJune 2024October 2025Allow1611NoNo
18720668MULTIPLE KASP MARKER PRIMER SET FOR WHEAT PLANT HEIGHT MAJOR GENES AND USE THEREOFJune 2024February 2026Allow2010NoNo
18739680KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCERJune 2024June 2025Allow1311NoNo
18668987TRANSMEMBRANE PORE CONSISTING OF TWO CSGG PORESMay 2024March 2026Allow2211NoNo
18665479ENRICHMENT OF CIRCULATING TUMOR DNAMay 2024May 2025Allow1230YesNo
18662886METHOD FOR EVALUATING TEA PLANT (+)-CATECHIN CONTENTMay 2024January 2025Allow810NoNo
18646971Kit for Assaying AFP mRNA for Liver Cancer DiagnosisApril 2024January 2025Abandon810NoNo
18640645METHODS OF DETECTING SPATIAL HETEROGENEITY OF A BIOLOGICAL SAMPLEApril 2024June 2025Allow1411NoNo
18636932EX VIVO METHOD FOR THE PROGNOSIS OF METASTASIS IN PROSTATE CANCERApril 2024March 2026Abandon2301NoNo
18633462METHODS OF PREPARING A DNA FRACTION ENRICHED WITH CIRCULATING TUMOR DNAApril 2024October 2024Allow620YesNo
18632749CELL-FREE DETECTION OF METHYLATED BREAST TUMORApril 2024January 2026Allow2111YesNo
18632776CELL-FREE DETECTION OF METHYLATED PROSTATE TUMOURApril 2024January 2026Allow2111YesNo
18625354COMPOSITIONS AND METHODS FOR DETECTION OF VIRAL PATHOGENS IN SAMPLESApril 2024March 2026Allow2321YesNo
18624594DETECTION METHODSApril 2024August 2025Allow1711YesNo
18622344NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENTMarch 2024August 2025Allow1710NoNo
18622489MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCEMarch 2024January 2025Allow1010NoNo
18615301Compositions and Methods for Analyzing Modified NucleotidesMarch 2024December 2025Allow2110NoNo
18614496METHOD OF MEASURING CHIMERISMMarch 2024May 2025Abandon1401NoNo
18444053METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF PANCREATIC CANCERFebruary 2024November 2024Allow911YesNo
18433345COMPOSITIONS AND METHODS FOR ANALYZING CELL-FREE DNA IN METHYLATION PARTITIONING ASSAYSFebruary 2024February 2026Allow2430YesNo
18430518METHYLATION CLASSIFIER FOR DETECTION OF HPV-INDUCED INVASIVE CANCERS, NONHPV-INDUCED GYNAECOLOGICAL AND ANOGENITAL CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONSFebruary 2024September 2024Allow800NoNo
18429449Application of Feature Gene TRIM22 in Preparation of Reagent Regulating Expression of Breast Cancer-Related GeneFebruary 2024March 2025Abandon1420NoNo
18430156METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUSFebruary 2024October 2024Allow810YesNo
18422247ASSAYS FOR FUNGAL INFECTIONJanuary 2024July 2025Allow1711YesNo
18421579ASSAYS FOR FUNGAL INFECTIONJanuary 2024April 2025Allow1410NoNo
18419411METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTSJanuary 2024October 2024Allow820YesNo
18418913EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERSJanuary 2024June 2025Allow1721YesNo
18412111PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINSJanuary 2024January 2025Abandon1210NoNo
18410950PERSONALIZED METHODS FOR DETECTING CIRCULATING TUMOR DNAJanuary 2024January 2026Abandon2440YesYes
18410474METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLEJanuary 2024May 2025Abandon1620NoNo
18408056KIT, DEVICE AND METHOD FOR DETECTING PROSTATE CANCERJanuary 2024January 2025Allow1211NoNo
18399181SINGLE-NUCLEOTIDE POLYMORPHISM LOCUS SIGNIFICANTLY RELATED TO YARDLONG BEAN ANTHOCYANIN CONTENT, KOMPETITIVE ALLELE-SPECIFIC POLYMERASE CHAIN REACTION MARKERS AND APPLICATION THEREOFDecember 2023January 2026Allow2510YesNo
18394729SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERSDecember 2023December 2024Allow1110NoNo
18394161GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTSDecember 2023October 2025Allow2211YesNo
18393314METHOD FOR ISOLATING TARGET NUCLEIC ACID USING HETERODUPLEX BINDING PROTEINSDecember 2023February 2026Abandon2610NoNo
18391117MULTIPLEXED FUEL ANALYSISDecember 2023June 2025Allow1800NoNo
18537520METHODS, PROBE SETS, AND KITS FOR DETECTION OF DELETION OF TUMOR SUPPRESSOR GENES BY FLUORESCENCE IN SITU HYBRIDIZATIONDecember 2023December 2025Abandon2431YesNo
18535773MLH1 METHYLATION ASSAYDecember 2023July 2025Allow1920NoNo
18534929SEQUENCING METHODS AND COMPOSITIONS FOR PRENATAL DIAGNOSESDecember 2023September 2025Allow2111YesNo
18530860METHODS OF DETECTING A LEAK FROM A SUBARRAY OF A MICROARRAY CHIP, KITS OF COMPONENTS THAT FACILITATE LEAK DETECTION, AND MICROARRAY CHIPS CONFIGURED FOR LEAK DETECTIONDecember 2023September 2024Allow921YesNo
18527076METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORSDecember 2023August 2025Abandon2111NoNo
18524829TARGETED RARE ALLELE CRISPR ENRICHMENTNovember 2023February 2026Abandon2620NoNo
18522844Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA)November 2023February 2026Allow2721NoNo
18521390THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASESNovember 2023March 2025Abandon1501NoNo
18517748Extracellular mRNA Markers of Muscular Dystrophies in Human UrineNovember 2023May 2025Abandon1810NoNo
18518079METHOD FOR PARENT-OF-ORIGIN DISEASE ALLELE DETECTION FOR THE DIAGNOSIS AND MANAGEMENT OF GENETIC DISEASESNovember 2023November 2024Allow1221YesNo
18517524DNA LOCATION METHOD AND APPARATUSNovember 2023April 2025Abandon1730NoYes
18518055CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCERNovember 2023April 2025Abandon1601NoNo
18513107THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCERNovember 2023December 2024Abandon1310NoNo
18508945DETECTING GASTRIC NEOPLASMNovember 2023January 2026Allow2611YesNo
18504402COMBINATIONS, DETECTION METHODS AND KITS OF DNA METHYLATION BIOMARKERNovember 2023July 2025Allow2011YesNo
18500680PREPARATION OF TEMPLATES FOR METHYLATION ANALYSISNovember 2023April 2025Allow1711YesNo
18385099SYSTEM FOR DETECTING AND CHARACTERIZING A MICROORGANISMOctober 2023February 2026Allow2810NoNo
18489096DETECTING NEOPLASMOctober 2023July 2025Allow2112NoNo
18379480LYSIS BUFFERS FOR EXTRACTING NUCLEIC ACIDSOctober 2023October 2025Abandon2411YesNo
18379355EXTRACT FROM A BODY FLUID COMPRISING A MICRO RNAOctober 2023June 2025Allow2031NoNo
18464360C-RAF Mutants that Confer Resistance to RAF InhibitorsSeptember 2023August 2024Allow1121YesNo
18459068Compositions and Methods for Analyte DetectionAugust 2023March 2025Abandon1801NoNo
18240789METHODS OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASEAugust 2023August 2025Allow2330NoNo
18457770METHODS FOR EARLY DETECTION OF CANCERAugust 2023June 2025Abandon2110NoNo
18457040METHOD FOR DETERMINATION OF CELLULAR MRNAAugust 2023July 2025Allow2311NoNo
18454312Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal CancerAugust 2023May 2025Allow2111NoNo
18452778CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSISAugust 2023May 2025Allow2110NoNo
18451574METHOD OF DIAGNOSIS, STAGING AND MONITORING OF MELANOMA USING MICRORNA GENE EXPRESSIONAugust 2023August 2025Allow2421NoNo
18450103CIRCULATING SERUM CELL-FREE DNA BIOMARKERS AND METHODSAugust 2023July 2024Allow1101NoNo
18446093SYSTEM, METHOD, COMPUTER-ACCESSIBLE MEDIUM AND APPARATUS FOR DNA MAPPINGAugust 2023July 2025Allow2310NoNo
18366436METHOD OF PREDICTING RISK OF RECURRENCE OF CANCERAugust 2023October 2025Allow2611NoNo
18230601METHODS FOR TREATING NEUROBLASTOMAAugust 2023May 2025Abandon2210NoNo
18229064LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSIONAugust 2023October 2025Abandon2610NoNo
18262812P27 SINGLE-NUCLEOTIDE POLYMORPHISM T2871099G AS A PREDICTOR OF THE BENEFIT OF ENDOCRINE THERAPY ALONE OR IN COMBINATION WITH CDK INHIBITORS IN BREAST CANCERJuly 2023March 2026Allow3201YesNo
18350566HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOFJuly 2023December 2024Abandon1701NoNo
18349807KIT FOR DIAGNOSING GASTRIC CANCER USING miRNA EXPRESSIONJuly 2023January 2025Abandon1810NoNo
18344010MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSESJune 2023January 2026Allow3131NoNo
18339400KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCERJune 2023October 2024Allow1611YesNo
18338974TARGETED MEASURE OF TRANSCRIPTIONAL ACTIVITY RELATED TO HORMONE RECEPTORSJune 2023November 2025Allow2940YesNo
18336450CONTROLS FOR PROXIMITY DETECTION ASSAYSJune 2023October 2025Abandon2840YesYes
18208770NUCLEIC ACID SEQUENCING ADAPTERS AND USES THEREOFJune 2023September 2025Allow2720NoNo
18332781ANALYTICAL METHODS FOR CELL FREE NUCLEIC ACIDS AND APPLICATIONSJune 2023January 2025Abandon2001NoNo
18332648BIOMARKER PANEL AND METHODS FOR DETECTING MICROSATELLITE INSTABILITY IN CANCERSJune 2023August 2025Allow2721YesNo
18330112METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSISJune 2023August 2024Allow1511NoNo
18328070STRATIFICATION AND PROGNOSIS OF CANCERJune 2023November 2024Abandon1710NoNo
18327614DETECTING OVARIAN CANCERJune 2023June 2025Allow2521NoNo
18325500Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M VariationMay 2023December 2024Allow1920YesNo
18037361SENSITIVE QUANTITATIVE DETECTION OF SARS-CoV-2 USING DIGITAL WARM-START CRISPR ASSAYMay 2023October 2025Allow2910YesNo
18314056COMPOSITIONS AND METHODS FOR ISOLATING CELL-FREE DNAMay 2023August 2025Allow2831NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1682.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
7
(41.2%)
Examiner Reversed
10
(58.8%)
Reversal Percentile
96.4%
Higher than average

What This Means

With a 58.8% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
169
Allowed After Appeal Filing
59
(34.9%)
Not Allowed After Appeal Filing
110
(65.1%)
Filing Benefit Percentile
64.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 34.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1682 - Prosecution Statistics Summary

Executive Summary

Art Unit 1682 is part of Group 1680 in Technology Center 1600. This art unit has examined 1,285 patent applications in our dataset, with an overall allowance rate of 82.0%. Applications typically reach final disposition in approximately 44 months.

Comparative Analysis

Art Unit 1682's allowance rate of 82.0% places it in the 71% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1682 receive an average of 2.58 office actions before reaching final disposition (in the 89% percentile). The median prosecution time is 44 months (in the 6% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.